In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

LeukoSite Inc.

Division of Takeda Pharmaceutical Co. Ltd.
www.leukosite.com

Latest From LeukoSite Inc.

Amazon Versus Biotech: How The IPO Class Of '97 Worked Out

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

Financing Growth

Takeda’s Tachi Yamada Discusses The Late-Stage Pipeline: An Interview At PSA 2013

In an interview with “The Pink Sheet” at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business and of the key late-stage assets that will carry the company into the next decade.

BioPharmaceutical Research & Development

The Alnylam Turnaround: What Changed Investors’ Minds?

Alnylam’s release of early-stage clinical data for its lead amyloidosis project in July caused a surge in its market value and rare cheers from investors. Years removed from its most recent high-profile technology deal, Alnylam is a company on the verge of completing the trickiest metamorphosis in biotech: from technology platform to product focus without the benefit of transformational M&A.

BioPharmaceutical Strategy

What Keeps Cancer Drug Developers Awake at Night

The range of comments, as well as the general tone, of a recent clinical cancer meeting prompted us to ask developers of cancer drugs what they saw as the major issues and hurdles in designing and testing new compounds. Their comments suggest that empirical methodologies, albeit informed by understanding of the biology around a target, will dominate clinical thinking in the near term. Clinical setbacks over the past several years, a lack of validated biomarkers, and an awareness that preclinical models are of limited utility in establishing dose and identifying likely responders, have reinforced that perception. Developers' principal concerns therefore often focus on things that are within their control; in particular, how to resource and manage a program for the long haul.
BioPharmaceutical Medical Device
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register